Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641841 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL11520049 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL935889 | 0.82 | GAA (0.50) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL30373084 | 0.81 | ALDH1A1 (0.42) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL16961526 | 0.81 | TTR (0.47) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL14645844 | 0.81 | ALDH1A1 (0.49) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL30373127 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL30373102 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL26088854 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL26088496 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697710-B | Novel substituted cyanoindoline derivatives as NIK inhibitors | 杨森制药有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-23 | — | — | US | disclosed |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-25 | — | — | US | disclosed |
| EP-3405196-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | Janssen Pharmaceutica NV (BE) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017125530-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-27 | — | — | WO | disclosed |
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20150239842-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239842-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239842-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2900653-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | Pfizer Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | KDM4E 1897/4885ALDH1A1 4296/4885HPGD 1127/4885 |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | KDM4E 1951/4885ALDH1A1 4076/4885HPGD 881/4885 |
| US-20150239842-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | HRH2, H1-0, H1-2 | KDM4E 1331/4885ALDH1A1 1457/4885HPGD 2270/4885 |
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | HRH2, HRH4, H1-0 | KDM4E 1062/4885ALDH1A1 1921/4885HPGD 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.